Is Abbott Laboratories (ABT) a risky stock?
As of July 21, 2026, Clavix grades Abbott Laboratories (ABT) A- for risk, a composite score of 78 out of 100 on an A+ to F scale, which puts ABT in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind ABT's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ABT scores on each, as of July 21, 2026.
What's moving ABT's risk right now
Company-specific signals Clavix flags behind ABT's current grade, drawn from recent news and filings as of July 21, 2026.
Two hacker groups are claiming separate breaches of Abbott's systems at the same time, raising potential HIPAA-related regulatory exposure and reputational risk while the scope is still being investigated.
Recent data frames Abbott as a more resilient, multi-segment growth story than previously perceived, which could support a higher valuation and ease concerns about overreliance on any single business.
What a A- grade means
On the Clavix A+ to F scale, ABT's composite of 78 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ABT or any security. Grades are risk indicators, not predictions of return. Data may be delayed.